Health care startup Paige has raised an additional $15 million from Goldman Sachs to help diagnose cancer using computer vision trained on clinical imaging data. The funding shows that while COVID-19 investments are getting a lot of attention, AI-related efforts to fight cancer are also moving forward. The idea is to use data sets related to treatment and genomics to train deep learning networks to detect breast, prostate, and other major cancers. Paige builds computational pathology products to help pathologists deliver more accurate diagnoses to cancer patients and allow patients and their care teams to make faster, more informed treatment decisions. New York-based Paige has raised over $95 million to date.

Paige, a NYC-based leader in computational pathology transforming the diagnosis and treatment of cancer, today announced it has closed its Series B funding round of $45 million, bringing the Company's total capital raised to over $70 million. Healthcare Venture Partners brought the largest contribution to the round, with Breyer Capital, Kenan Turnacioglu, and other funds participating. Paige will use this new capital to drive FDA clearance of its products and expand its portfolio, delving deeper into cancer pathology, novel biomarkers, and prognostic capabilities. Additionally, the Company will accelerate commercial efforts in the U.S. and expansion in Europe, Brazil, and Canada. Pathology is the cornerstone of cancer diagnoses.